Fetuin-A is a hepatokine that contributes to MASLD pathogenesis primarily by promoting insulin resistance and amplifying TLR-4 (toll-like receptor 4)—mediated inflammatory signaling, thereby linking metabolic disturbances with hepatic steatosis and fibrosis [71,72,73,74]. Here, AHSG is linked to metabolic dysfunction-associated steatotic liver disease.